Ipsen provides update on legacy of Henri Beaufour
PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed…
IndiaFirst Life Enters Strategic Corporate Agency Tie-Up with Dombivli Nagari Sahakari Bank
MUMBAI, India, Dec. 4, 2025 /PRNewswire/ -- IndiaFirst Life Insurance Company Ltd.…
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected…
TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact
Through this annual program, TraceLink champions global health equity, community resilience, and…
Interlace Showcases “Capital Agility” as the New Corporate Financial Edge at Hong Kong FinTech Week 2025
HONG KONG, Nov. 5, 2025 /PRNewswire/ -- November 3–7, 2025 – Hong…
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 31, 2025 16:30 ET | Source: FibroBiologics, Inc. Advancing preparations to…
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
Alps Blockchain Announces Corporate Rebranding to Alps
Reflecting its evolution into a global builder of next-generation data center infrastructure…
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus…
Renewal Fuels, Inc. Announces Comprehensive Corporate Reset and Strategic Growth Initiative
LAS VEGAS, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Renewal Fuels, Inc. (OTC:…
